Clovis Lusivika-Nzinga Selected Research

sotrovimab

10/2022	Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.
1/2022	Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Clovis Lusivika-Nzinga Research Topics

Disease

3	COVID-19 10/2022 - 11/2021
3	Chronic Hepatitis C 06/2022 - 12/2019
3	Fibrosis (Cirrhosis) 06/2022 - 12/2019
2	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 12/2019
2	Infections 10/2020 - 12/2019
1	Esophageal and Gastric Varices (Esophageal Varices) 06/2022
1	Hypercholesterolemia 06/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Chronic Hepatitis B 01/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021
1	Fatigue 10/2020
1	Headache (Headaches) 10/2020
1	Hepatitis 10/2020
1	Asthenia 10/2020
1	Coinfection 12/2019
1	Anus Neoplasms (Anal Cancer) 12/2017

Drug/Important Bio-Agent (IBA)

3	Antiviral Agents (Antivirals)IBA 06/2022 - 12/2019
2	sotrovimabIBA 10/2022 - 01/2022
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 10/2022
1	AlbuminsIBA 06/2022
1	BilirubinIBA 06/2022
1	AntibodiesIBA 11/2021
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	daclatasvirIBA 10/2020
1	Ribavirin (Virazole)FDA LinkGeneric 10/2020
1	SofosbuvirIBA 10/2020
1	Protease Inhibitors (Protease Inhibitor)IBA 12/2017

Therapy/Procedure

2	Liver Transplantation 01/2021 - 12/2019
2	Therapeutics 01/2021 - 12/2019
1	Aftercare (After-Treatment) 06/2022